- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00277511
Levofloxacin, Chronic Bacterial Prostatitis
October 11, 2007 updated by: Sanofi
Prospective, Multinational, Multicenter, Non-Comparative, Open Study With a 6 Months Follow-up Period to Demonstrate the Efficacy and Safety of Oral Levofloxacin 500 mg Once Daily in the Treatment of Chronic Bacterial Prostatitis (CBP)
Primary objective:
- To investigate the microbiological efficacy, assessed as eradication rate based on microbiologically evaluable patients 1 month post treatment with oral Levofloxacin 500 mg in male adults with chronic bacterial prostatitis (CBP, category II)
Secondary objectives:
- To investigate the microbiological efficacy, assessed as eradication rate based on microbiologically evaluable patients 6 months post treatment with oral Levofloxacin 500 mg in male adults with chronic bacterial prostatitis (CBP, category II).
- To assess the clinical response rate based on resolution of signs and symptoms after 2 weeks of treatment; 5-12 days, 1 month, 3 months and 6 months post treatment with oral Levofloxacin 500 mg in male adults with chronic bacterial prostatitis (CBP, category II).
- To assess the safety of Levofloxacin 500 mg on the basis of adverse events, standard clinical chemistry, hematology, urinalysis and vital signs in male adults with chronic bacterial prostatitis (CBP, category II).
Study Overview
Study Type
Interventional
Enrollment
120
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany
- Sanofi-Aventis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Subjects meeting all of the following criteria will be considered for enrollment into the study:
A clinical diagnosis of chronic prostatitis as evidenced by the following criteria:
- clinical signs and symptoms of prostatitis and
- a history of chronic prostatitis as defined as: symptomatic prostatitis (a clinical diagnosis of prostatitis having been made for at least one previous episode which episode having lasted four weeks or two or more other episodes during the previous twelve months) and leucocyturia greater/equal 10 WBC/HPF x 400
- Laboratory evidence of prostatitis
- Candidate is appropriate for oral therapy.
- OTC medications for chronic prostatitis (other than antibiotics), which the subject has been receiving must continue throughout the study at the same dose or be discontinued prior to study entry.
Exclusion Criteria:
Subjects presenting with any of the following will not be included in the study:
- Need for parenteral therapy for the treatment of chronic bacterial prostatitis (CBP, Category II)
- Subjects with pathogen known or suspected to be resistant to the study drug
- Requirement for a second systemic antibacterial regimen
- Any condition which may interfere with the evaluation of the study drug including transurethral prostatectomy within 6 months of enrollment, the presence of a permanent transurethral catheter or a history of cystostomy or nephrostomy
- Taking medication that may effect bladder or prostate function (e.g. hormone therapy anticholinergics or alpha-blocker)
- Patients not receiving saw palmetto at the time of study entry should not start treatment with saw palmetto within 10 weeks of study entry
- Known prostatic carcinoma
- The presence of another infection requiring therapy with an antibacterial other than the study drug
- Greater than 24 hours of potentially effective therapy within seven days prior to study when there is documented evidence of a resistant organism or clinical failure after five or more days of previous antibacterial therapy
- History of hypersensitivity to the investigational product or to drugs with similar chemical structures
- History of tendonitis or tendon rupture
- Treatment with other quinolones in the last 14 days before study entry
- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.
- Treatment with any investigational product in the last 30 days before study entry
- Clinically relevant cardiovascular, hepatic, neurologic, endocrine or other major systemic disease making implementation of the protocol or interpretation of the study results difficult
- History of drug or alcohol abuse
Impaired hepatic function, as shown by:
- AST (SGOT) greater/equal 3 times the upper limit of the reference range
- ALT (SGPT) greater/equal 3 times the upper limit of the reference range
- bilirubin greater 51 µmol/l, i.e., greater 3 mg/dl (except of Gilbert disease)
- hepatic encephalopathy
- Impaired renal function, as shown by either creatinine clearance smaller 50 ml/min or undergoing hemodialysis or peritoneal dialysis (creatinine clearance may be estimated by formula or nomogram)
- Underweight (40 kg or less)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary efficacy data will be determined by eradication rate based on microbiologically evaluable subjects, evaluated for each pathogen and subject.
Time Frame: determined at 1 month follow-up
|
determined at 1 month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary efficacy data will be determined by microbiological eradication rate
Time Frame: at 6 months follow-up
|
at 6 months follow-up
|
clinical response rate based on resolution of signs and symptoms
Time Frame: after 2 weeks of treatment and during follow-up period.
|
after 2 weeks of treatment and during follow-up period.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Katrin Roscher, Sanofi
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2003
Study Registration Dates
First Submitted
January 13, 2006
First Submitted That Met QC Criteria
January 13, 2006
First Posted (Estimate)
January 16, 2006
Study Record Updates
Last Update Posted (Estimate)
October 12, 2007
Last Update Submitted That Met QC Criteria
October 11, 2007
Last Verified
October 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Prostatic Diseases
- Prostatitis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Anti-Infective Agents, Urinary
- Renal Agents
- Levofloxacin
- Ofloxacin
Other Study ID Numbers
- HR355/3036
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatitis
-
Aziende Chimiche Riunite Angelini Francesco S.p.AHippocrates ResearchCompleted
-
University of Roma La SapienzaCompleted
-
Ain Shams UniversityCompletedDutasteride | Category IIIB Chronic ProstatitisEgypt
-
Cairo UniversityUnknownChronic Non Bacterial Prostatitis
-
Second Affiliated Hospital, School of Medicine,...Peking University First Hospital; Changhai Hospital; First Affiliated Hospital... and other collaboratorsUnknown
-
Ahlia UniversityCairo UniversityCompletedChronic Non-bacterial ProstatitisEgypt
-
Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedCystitis, Interstitial | Painful Bladder Syndrome | Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Bacterial Prostatitis | Asymptomatic Inflammatory ProstatitisUnited States
-
National Institute of Diabetes and Digestive and...CompletedChronic Prostatitis With Chronic Pelvic Pain Syndrome
-
Institute for the Study of Urological Diseases,...CompletedChronic ProstatitisGreece
-
SPP Pharmaclon Ltd.Completed
Clinical Trials on Levofloxacin
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
University of KarachiMerck Pvt. Ltd, Pakistan; Center for bioequivalence studies and clinical reseach...Completed
-
University of RochesterCompletedChronic RhinosinusitisUnited States
-
Indonesia UniversityEnrolling by invitationUrinary Tract InfectionsIndonesia
-
University of MonastirCompletedChronic Obstructive Pulmonary DiseaseTunisia
-
University of MonastirCompletedChronic Obstructive Pulmonary DiseaseTunisia
-
Indiana University School of MedicineCompletedCataractUnited States
-
InnocollPremier Research Group plcCompletedDiabetic Foot UlcerUnited States
-
Mackay Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
-
University of LatviaNational Institute of Public Health, Slovenia; Iuliu Hatieganu University of... and other collaboratorsRecruitingGastric Cancer | H Pylori Infection | H Pylori Eradication | H-pyloriPoland, Croatia, Ireland, Latvia, Romania, Slovenia